The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery
NCT ID: NCT06798714
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
140 participants
INTERVENTIONAL
2025-01-20
2026-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is planned to recruit 70 patients who will undergo pericardial fenestration during the operation using the original technique during coronary artery bypass grafting (Patent No. 2647626 C1 Russian Federation), and will be prescribed colchicine (the drug "Colchicum-dispert") in the perioperative period in order to prevent the development of paroxysms of atrial fibrillation in the postoperative period, and 70 cardiac surgery patients operated on using the standard technique (without performing the pericardial fenestration procedure intraoperatively), receiving non-steroidal anti-inflammatory drugs in the postoperative period.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation
NCT02177266
Colchicine's Effect on Inflammatory Markers
NCT07287345
Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass
NCT03500783
Feasibility of Perioperative Stellate Ganglion Blocks in Cardiac Surgery
NCT02784587
Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG
NCT03905759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
1. To assess the risk factors that influence the development of atrial fibrillation in the early postoperative period;
2. To conduct a comparative analysis of various therapy methods to reduce the risk of developing atrial fibrillation paroxysms in the early postoperative period in cardiac surgery patients.
To solve the set tasks, it is planned to conduct a cohort prospective observational study of patients with coronary artery disease who underwent coronary artery bypass grafting with cardiopulmonary bypass.
Duration of the study - 1,5 years. The observation period for patients is the hospital postoperative period after CABG.
The study is planned to include 140 patients diagnosed with coronary heart disease. The diagnosis will be established on the basis of medical records and coronary angiography. Indications for CABG surgery will be determined by a consulting cardiac surgeon in accordance with the current Clinical Guidelines of the Ministry of Health of the Russian Federation "Stable ischemic heart disease" (2020).
Patients should be over 18 years old. It is planned to recruit 70 patients who will undergo pericardial fenestration during coronary artery bypass grafting using the original technique (Patent No. 2647626 C1 Russian Federation), and will be prescribed colchicine (the drug "Colchicum-dispert") in the perioperative period in order to prevent the development of paroxysms of atrial fibrillation in the postoperative period, and 70 cardiac surgery patients operated on using the standard technique (without performing the pericardial fenestration procedure intraoperatively), receiving non-steroidal anti-inflammatory drugs in the postoperative period. Diclofenac will be used as an NSAID in the postoperative period at a daily dose of 100 mg (orally). Colchicine (trade name of the drug "Colchicum-dispert") will be prescribed in a dose of 500 micrograms 4 hours before surgery and 500 micrograms 2 times a day for 10 days after surgery. Since the drug is not registered for the prevention of atrial fibrillation in the postoperative period, its prescription will be decided by a council of doctors, including at least 3 people (head of the department, attending physician, and research physician).
Safety evaluation Since no medical studies or interventions will be carried out in addition to what the patient should receive during standard examination and treatment, participation in this study does not entail any risks and threats to the patient.
The safety endpoints of standard treatment for this disease will be analyzed. Statistical analysis Statistical analysis of data will be carried out in the STATISTICA 10 StatSoft program. Inc. 1984-2011 (USA). Quantitative values will be displayed as median and quartiles Me \[25;75\]. Comparison of quantitative characteristics between groups will be performed using the Mann-Whitney U-test. Fisher's exact test will be used to compare qualitative characteristics. Differences will be considered statistically significant at p \< 0.05.
Ethical and legal issues of the study:
The study was approved by the Biomedical Ethics Committee at Cardiology Research Institute of Tomsk National Research Medical Center.
All patients must sign an informed consent form allowing the use of information about their examination and treatment for scientific purposes with subsequent publication of materials in the open press. The study will be conducted in accordance with the current version of the Declaration of Helsinki, the provisions of the National Standard of the Russian Federation GOST R52379-2005 on Good Clinical Practice dated April 1, 2006, the Order of the Ministry of Health of the Russian Federation dated April 1, 2016 No. 200n "On approval of the rules of good clinical practice" and the provisions of Good Clinical Practice (GCP).
The procedure for informing study subjects and obtaining written consent from them will be carried out in accordance with GCP standards.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Group 2 (n=70). Patients operated on using the standard technique (CABG without pericardial fenestration) and receiving NSAIDs in the postoperative period.
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Standard technique without performing the pericardial fenestration procedure intraoperatively. Standard postoperative treatment
NSAID
standard CABG without performing pericardial fenestration intraoperatively
Experimental group
Pericardial fenestration during coronary artery bypass grafting using the original technique.
Colchicine (Colchicum-dispert) administration 4 hours before surgery and for 10 days after surgery
Colchicine 0.5 MG
Colchicine will be prescribed in a dose of 500 micrograms 4 hours before surgery and 500 micrograms 2 times a day for 10 days after surgery with pericardial fenestration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NSAID
standard CABG without performing pericardial fenestration intraoperatively
Colchicine 0.5 MG
Colchicine will be prescribed in a dose of 500 micrograms 4 hours before surgery and 500 micrograms 2 times a day for 10 days after surgery with pericardial fenestration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. signed informed consent to participate in the study.
Exclusion Criteria
2. Valvular heart disease requiring surgical correction;
3. Liver failure with an increase in liver transaminases ≥1.5 times;
4. Renal failure (GFR\<35 mL/min/1.73 m2 calculated with CKD-EPI);
5. Permanent, persistent or paroxysmal atrial fibrillation;
6. Previously implanted pacemaker;
7. Hypersensitivity to colchicine;
8. Neutropenia;
9. History of alcoholism;
10. Refusal to sign informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tomsk Cardiology Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuri Y Vechersky, PhD
Role: PRINCIPAL_INVESTIGATOR
Cardiology Research Institute, Tomsk National Research Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
Tomsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Diakova ML, Kuznetsov MS, Vechersky YY, Kim EB, Zyryanov SV, Petlin KA, Kozlov BN. A Combined Approach to the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery. Biomedicines. 2025 Aug 17;13(8):1999. doi: 10.3390/biomedicines13081999.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Рег. № 123051500130-9:
Identifier Type: REGISTRY
Identifier Source: secondary_id
Tomsk Cardiology Research Inst
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.